Bio-Path Holdings (BPTH)
(Real Time Quote from BATS)
$2.59 USD
+0.10 (4.02%)
Updated Apr 25, 2024 03:18 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
BPTH 2.59 +0.10(4.02%)
Will BPTH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BPTH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BPTH
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
BPTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BPTH
Bio-Path files to sell 484K shares of common stock for holders
Bio-Path files to sell 484K shares of common stock for holders
Bio-Path Holdings, Sunshine Biopharma, INVO Bioscience among healthcare movers
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
12 Health Care Stocks Moving In Monday's Intraday Session